Martin Mackay - 21 May 2025 Form 4 Insider Report for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)

Role
Director
Signature
/s/ Martin Mackay
Issuer symbol
CRL
Transactions as of
21 May 2025
Net transactions value
+$517,918
Form type
4
Filing time
23 May 2025, 16:19:56 UTC
Previous filing
15 May 2025
Next filing
02 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MACKAY MARTIN Director C/O CHARLES RIVER LABORATORIES, 251 BALLARDVALE STREET, WILMINGTON /s/ Martin Mackay 23 May 2025 0001414815

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRL Common Stock Award $127,691 +946 +7.5% $134.98 13,477 21 May 2025 Direct F1
transaction CRL Common Stock Award $110,009 +815 +6% $134.98 14,292 21 May 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRL Stock Options (Right to Buy) Award $280,218 +2,076 $134.98 2,076 21 May 2025 Common Stock 2,076 $134.98 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The unvested restricted stock units vest upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders.
F2 The grant was made in lieu of director service fees for the term commencing May 20, 2025. The restricted stock units vest upon the earlier of 5/21/2026, or the business day prior to the Company's next annual meeting of shareholders.
F3 The stock options become exercisable upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders.